Cargando…

P53- and mevalonate pathway–driven malignancies require Arf6 for metastasis and drug resistance

Drug resistance, metastasis, and a mesenchymal transcriptional program are central features of aggressive breast tumors. The GTPase Arf6, often overexpressed in tumors, is critical to promote epithelial–mesenchymal transition and invasiveness. The metabolic mevalonate pathway (MVP) is associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hashimoto, Ari, Oikawa, Tsukasa, Hashimoto, Shigeru, Sugino, Hirokazu, Yoshikawa, Ayumu, Otsuka, Yutaro, Handa, Haruka, Onodera, Yasuhito, Nam, Jin-Min, Oneyama, Chitose, Okada, Masato, Fukuda, Mitsunori, Sabe, Hisataka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828690/ https://www.ncbi.nlm.nih.gov/pubmed/27044891 http://dx.doi.org/10.1083/jcb.201510002

Ejemplares similares

Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer
por: Hashimoto, Shigeru, et al.
Publicado: (2016)

Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model
por: Otsuka, Yutaro, et al.
Publicado: (2018)

Epithelial-specific histone modification of the miR-96/182 locus targeting AMAP1 mRNA predisposes p53 to suppress cell invasion in epithelial cells
por: Handa, Haruka, et al.
Publicado: (2018)

Necessity of p53-binding to the CDH1 locus for its expression defines two epithelial cell types differing in their integrity
por: Oikawa, Tsukasa, et al.
Publicado: (2018)

Arf6 and its ZEB1-EPB41L5 mesenchymal axis are required for both mesenchymal- and amoeboid-type invasion of cancer cells
por: Handa, Haruka, et al.
Publicado: (2017)

High expression of EPB41L5, an integral component of the Arf6-driven mesenchymal program, correlates with poor prognosis of squamous cell carcinoma of the tongue
por: Otsuka, Yutaro, et al.
Publicado: (2016)

ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance
por: Hashimoto, A, et al.
Publicado: (2016)

ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
por: Hashimoto, Shigeru, et al.
Publicado: (2019)

ARF1 recruits RAC1 to leading edge in neutrophil chemotaxis
por: Mazaki, Yuichi, et al.
Publicado: (2017)

The EGFR-GEP100-Arf6-AMAP1 Signaling Pathway Specific to Breast Cancer Invasion and Metastasis(†)
por: Sabe, Hisataka, et al.
Publicado: (2009)

Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer
por: Hashimoto, Ari, et al.
Publicado: (2021)

Engagement of Overexpressed Her2 with GEP100 Induces Autonomous Invasive Activities and Provides a Biomarker for Metastases of Lung Adenocarcinoma
por: Menju, Toshi, et al.
Publicado: (2011)

Co-Overexpression of GEP100 and AMAP1 Proteins Correlates with Rapid Local Recurrence after Breast Conservative Therapy
por: Kinoshita, Rumiko, et al.
Publicado: (2013)

p53-Dependent and -Independent Epithelial Integrity: Beyond miRNAs and Metabolic Fluctuations
por: Oikawa, Tsukasa, et al.
Publicado: (2018)

High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer
por: Tsutaho, Akio, et al.
Publicado: (2020)

Rab5c promotes AMAP1–PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion
por: Onodera, Yasuhito, et al.
Publicado: (2012)

Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe
por: Onodera, Yasuhito, et al.
Publicado: (2018)

GEP100-Arf6-AMAP1-Cortactin Pathway Frequently Used in Cancer Invasion Is Activated by VEGFR2 to Promote Angiogenesis
por: Hashimoto, Ari, et al.
Publicado: (2011)

KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion
por: Sabe, Hisataka
Publicado: (2023)

Dual roles of AMAP1 in the transcriptional regulation and intracellular trafficking of carbonic anhydrase IX
por: Horikawa, Mei, et al.
Publicado: (2021)

Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma
por: Hashimoto, Ari, et al.
Publicado: (2022)

Pag3/Papα/Kiaa0400, a Gtpase-Activating Protein for Adp-Ribosylation Factor (Arf), Regulates Arf6 in Fcγ Receptor–Mediated Phagocytosis of Macrophages
por: Uchida, Hiroshi, et al.
Publicado: (2001)

EPB41L5 functions to post-transcriptionally regulate cadherin and integrin during epithelial–mesenchymal transition
por: Hirano, Mariko, et al.
Publicado: (2008)

Cross-disease communication between cancer and heart failure provides a rational approach to prevention and treatment of both diseases
por: Takada, Shingo, et al.
Publicado: (2022)

AMAP1 as a negative-feedback regulator of nuclear factor-κB under inflammatory conditions
por: Tien, Dat Nguyen, et al.
Publicado: (2014)

High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients
por: Sato, Hiroki, et al.
Publicado: (2014)

GBF1 bears a novel phosphatidylinositol-phosphate binding module, BP3K, to link PI3Kγ activity with Arf1 activation involved in GPCR-mediated neutrophil chemotaxis and superoxide production
por: Mazaki, Yuichi, et al.
Publicado: (2012)

Arf6, Rab11 and transferrin receptor define distinct populations of recycling endosomes
por: Kobayashi, Hotaka, et al.
Publicado: (2013)

LRRK2 is involved in the chemotaxis of neutrophils and differentiated HL-60 cells, and the inhibition of LRRK2 kinase activity increases fMLP-induced chemotactic activity
por: Mazaki, Yuichi, et al.
Publicado: (2023)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

MicroRNA‐27b suppresses tumor progression by regulating ARFGEF1 and focal adhesion signaling
por: Matsuyama, Rei, et al.
Publicado: (2015)

Sensitive and rapid quantification of exosomes by fusing luciferase to exosome marker proteins
por: Hikita, Tomoya, et al.
Publicado: (2018)

In vivo imaging of long-term accumulation of cancer-derived exosomes using a BRET-based reporter
por: Hikita, Tomoya, et al.
Publicado: (2020)

Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome
por: Haas, Dorothea, et al.
Publicado: (2006)

Diagnostic value of urinary mevalonic acid excretion in mevalonate kinase deficiency (MKD)
por: Jeyaratnam, Jerold, et al.
Publicado: (2014)

Activation-Inactivation Cycling of Rab35 and ARF6 Is Required for Phagocytosis of Zymosan in RAW264 Macrophages
por: Egami, Youhei, et al.
Publicado: (2015)

ADP-Ribosylation Factor 6 Pathway Acts as a Key Executor of Mesenchymal Tumor Plasticity
por: Hashimoto, Ari, et al.
Publicado: (2023)

Roles of Raft-Anchored Adaptor Cbp/PAG1 in Spatial Regulation of c-Src Kinase
por: Saitou, Takashi, et al.
Publicado: (2014)

Src in endosomal membranes promotes exosome secretion and tumor progression
por: Hikita, Tomoya, et al.
Publicado: (2019)

A peptide derived from adaptor protein STAP-2 inhibits tumor progression by downregulating epidermal growth factor receptor signaling
por: Maemoto, Taiga, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_at77o7sav9joskipu28f311m7u